Main content

Evaluation of Repeated Intralesional Injection of Allogeneic Umbilical Equine Cord Blood Mesenchymal Stromal Cells for Treatment of Equine Superficial Digital Flexor Tendonitis

Show simple item record

dc.contributor.advisor Koenig, Judith Merchan Munoz, Alejandro 2023-01-20T14:46:46Z 2023-01-20T14:46:46Z 2023 2023-01-11
dc.description.abstract This thesis is a continuation of the investigations of cryopreserved allogeneic equine umbilical cord blood (CB) derived mesenchymal stromal cells (MSC) by its use in the treatment of superficial digital flexor tendon (SDFT) injuries in horses. In the course of time, the thesis concludes evaluating the efficacy and safety of repeated intralesional injection of CB-MSC in SDFT lesions in client-owned horses and its comparison to the control group receiving platelet rich plasma (PRP). We confirmed the safety of the CB-MSC with the results of the flow cytometry for lymphocytes CD4+ and CD8+ on the blood samples taken at 0, 24, 72 and 168 hours post-injection. There was no clinical systemic immune reaction to repeated CB-MSC treatment and there were no paraclinical significant changes as measured by the expression of lymphocytes CD4+ and CD8+ between groups, treatments, and injections times. We identified that the intralesional treatment of CB-MSC induced an inflammatory reaction at the injection site that resolved within 24 to 72 hours. Along with the inflammatory response, the patients displayed an expansion of the needle tract that was noticeable throughout the length of the study. In all horses, we used a 20-gauge needle to inject. Possibly, the horses had a mild reaction to the commercial cryomedium. Ultrasonographic evaluations revealed that circumferences of the lesion region decreased faster in the CB-MSC group compared to the PRP group. Four out of five horses in the CB-MSC group returned to racing as defined by one or more starts and one out of three patients in the PRP group returned to race training. Based on our results, the repeated intralesional treatment with allogeneic equine CB-MSC is safe, despite the inflammation and needle tract observed. We believe that an alternative delivery method of allogeneic equine CB-MSC that avoids the risk of needle-tracts is desirable. For that reason, we proposed the continuation of the current thesis with a clinical prospective study to investigate the use of repeated intra-arterial injections of allogeneic equine CB MSC for SDFT lesions, and to evaluate its utility. en_US
dc.description.sponsorship Equine Guelph. eQcell. Arthrex en_US
dc.language.iso en en_US
dc.publisher University of Guelph en
dc.subject CB-MSCs en_US
dc.subject PRP en_US
dc.subject SDFT en_US
dc.subject Regenerative therapy en_US
dc.subject Thoroughbred en_US
dc.title Evaluation of Repeated Intralesional Injection of Allogeneic Umbilical Equine Cord Blood Mesenchymal Stromal Cells for Treatment of Equine Superficial Digital Flexor Tendonitis en_US
dc.type Thesis en Clinical Studies en_US Doctor of Veterinary Science en_US Department of Clinical Studies en_US
dc.rights.license All items in the Atrium are protected by copyright with all rights reserved unless otherwise indicated. University of Guelph en

Files in this item

Files Size Format View
Merchan_Alejandro_202301_DVSc.pdf 2.418Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

The library is committed to ensuring that members of our user community with disabilities have equal access to our services and resources and that their dignity and independence is always respected. If you encounter a barrier and/or need an alternate format, please fill out our Library Print and Multimedia Alternate-Format Request Form. Contact us if you’d like to provide feedback:  (email address)